Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II infant pneumococcal vaccine immunogenicity and safety study of 2830929A and 2830930A
2011-005743-27Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GSK2830929A and GSK2830930A in pneumococcal disease (4 arms), sponsored by GSK. Primary endpoint: Evaluation of immune responses to components of the 2830929A and 2830930A vaccines. Started Feb 2012; status: completed.
02
Drugs
GSK2830929AGSK2830930A
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2011-005743-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005743-27.